Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILE: Dolutegravir + Darunavir/Ritonavir in Paediatric HIV
NCT02383108Phase 3Completed
- Sponsor
- Penta Foundation
- Start
- Jun 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Penta Foundation. Started Jun 2016; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02383108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383108.